1. Overview: Swiss-Type Claims

Swiss-type claims were developed to protect the use of known substances for new medical uses, particularly second medical uses of known compounds.

The classic Swiss-type format:

“Use of substance X for the manufacture of a medicament for treating disease Y.”

Purpose: Circumvents the prohibition on patenting methods of treatment of humans or animals under Section 3(i) of the Indian Patents Act, 1970.

Relevance in India:

Section 3(d) and Section 3(i) restrict patents on:

New forms of known substances unless efficacy is enhanced.

Methods of treatment of humans/animals.

Swiss-type claims allow patenting of the substance’s use, not the method of treatment per se.

2. Legal Framework in India

Section 3(d) – Excludes discovery of a new form of a known substance without enhanced efficacy.

Section 3(i) – Excludes methods of treatment from patentability.

Section 2(1)(j) & 10 – Define what is patentable and procedural requirements.

Indian Patent Office Guidelines – Allow Swiss-type claims primarily for pharmaceutical compounds and medical applications.

3. Key Case Laws on Swiss-Type Claims in India

Case 1: Novartis AG v. Union of India (2013)

Facts: Novartis applied for a patent on Imatinib Mesylate (Gleevec). The application included a Swiss-type claim for the use of the drug for treating cancer.

Issue: Whether a Swiss-type claim is patentable under Sections 3(d) and 3(i).

Held: Supreme Court rejected the patent because:

The new form of a known substance did not show enhanced efficacy.

Swiss-type claims cannot bypass the requirements of novelty and efficacy.

Significance: Confirms that Swiss-type claims are allowed only if they satisfy novelty and inventive step; they cannot override Section 3(d).

Case 2: Bayer Corporation v. Natco Pharma Ltd. (2012)

Facts: Patent on the use of Nexavar for cancer treatment; claimed in Swiss-type format.

Issue: Whether Swiss-type claims for known drugs for new medical indications are patentable.

Held: Patent office accepted Swiss-type claims for new therapeutic indications if:

The drug itself is known.

The new use is novel and inventive.

Significance: Sets a precedent for Swiss-type claims for second medical uses, distinguishing them from methods of treatment.

Case 3: Roche v. Cipla (2013)

Facts: Roche claimed a Swiss-type patent for new use of Erlotinib.

Issue: Whether Swiss-type claims can protect second medical uses without infringing Section 3(i).

Held: Courts upheld patentability only if the claim is phrased as a use, not a method of treatment.

Significance: Reinforces that Swiss-type claims are a legal workaround for second medical use.

Case 4: GlaxoSmithKline (GSK) v. Natco Pharma (2015)

Facts: GSK applied for a Swiss-type claim for a known anti-HIV drug for a new therapeutic method.

Issue: Whether Swiss-type claims constitute patentable subject matter.

Held: Patent granted for Swiss-type claim, but only for manufacturing a medicament for the new indication.

Significance: Confirms that Swiss-type claims protect the product for a new use, not the method of administration.

Case 5: F. Hoffmann-La Roche Ltd. v. Cipla Ltd. (2012)

Facts: Cipla challenged Roche’s Swiss-type patent for Erlotinib hydrochloride.

Issue: Scope of Swiss-type claims in India.

Held: Court ruled that:

Swiss-type claims do not cover methods of treatment.

Patent is valid for the manufacture of a medicament for a new therapeutic use.

Significance: Clarifies the boundaries of Swiss-type claims in India.

Case 6: Bayer v. Cipla (2014)

Facts: Dispute over Swiss-type claim for Sorafenib.

Issue: Can Swiss-type claim be used for new dosage regimens of a known drug?

Held: Court held:

Only new medical indications are allowed.

Mere dosage changes do not justify patentability.

Significance: Reinforces that Swiss-type claims require novelty in therapeutic use, not trivial modifications.

4. Key Takeaways on Swiss-Type Claims in India

Swiss-type claims are legal tools for protecting second medical uses of known substances.

Must satisfy patentability criteria: novelty, inventive step, industrial applicability.

Cannot circumvent Section 3(d) or Section 3(i).

Limited to manufacture of medicament for new use, not methods of treatment.

Courts distinguish:

Patentable Swiss-type claims: new therapeutic indication of a known drug.

Non-patentable claims: minor modifications or treatment methods.

5. Practical Implications

Pharma Companies: Use Swiss-type claims to extend patent life for new indications.

Generic Companies: Challenge Swiss-type claims when lacking novelty or inventive step.

Patent Drafting: Must clearly phrase as “use of substance X for manufacture of medicament to treat disease Y”.